PE20190130A1 - Secuencias de envoltura de flavivirus variante y usos de las mismas - Google Patents

Secuencias de envoltura de flavivirus variante y usos de las mismas

Info

Publication number
PE20190130A1
PE20190130A1 PE2018003079A PE2018003079A PE20190130A1 PE 20190130 A1 PE20190130 A1 PE 20190130A1 PE 2018003079 A PE2018003079 A PE 2018003079A PE 2018003079 A PE2018003079 A PE 2018003079A PE 20190130 A1 PE20190130 A1 PE 20190130A1
Authority
PE
Peru
Prior art keywords
sequence
flavivirus
flavivirus protein
asn
ser
Prior art date
Application number
PE2018003079A
Other languages
English (en)
Inventor
Peter Laing
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of PE20190130A1 publication Critical patent/PE20190130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion se refiere a analogos recombinantes aislados de bucles de fusion de proteina E de flavivirus que comprenden al menos un sitio de glicosilacion para un glicano ligado a N que no esta presente en la secuencia de bucle de fusion de proteina E de flavivirus natural , en el que al menos un sitio 5 de glicosilacion es un secuon de glicosilacion ligado a N (Asn - X- Ser/Thr) y el residuo Asn (N) del secuon ocupa cualquiera de las posiciones 98 - 110 (DRGWGNGCGLFGK) de la secuencia de aminoacidos del bucle de fusion de la proteina E del flavivirus natural, en el que X es cualquier residuo de aminoacido excepto prolina y Ser/ Thr denota un residuo de serina o treonina
PE2018003079A 2016-05-20 2017-05-22 Secuencias de envoltura de flavivirus variante y usos de las mismas PE20190130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Publications (1)

Publication Number Publication Date
PE20190130A1 true PE20190130A1 (es) 2019-01-17

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003079A PE20190130A1 (es) 2016-05-20 2017-05-22 Secuencias de envoltura de flavivirus variante y usos de las mismas

Country Status (18)

Country Link
US (2) US11028133B2 (es)
EP (2) EP3458471B1 (es)
JP (1) JP7121396B2 (es)
KR (1) KR20190008896A (es)
CN (1) CN109415414A (es)
AU (1) AU2017268479B2 (es)
BR (1) BR112018073681A2 (es)
CA (1) CA3025076A1 (es)
DK (1) DK3458471T3 (es)
GB (2) GB2550418A (es)
HU (1) HUE049543T2 (es)
IL (1) IL263054A (es)
MX (1) MX2018014198A (es)
PE (1) PE20190130A1 (es)
PH (1) PH12018502441A1 (es)
RU (1) RU2018142835A (es)
SG (1) SG11201810157QA (es)
WO (2) WO2017201543A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
WO2018208547A1 (en) * 2017-05-10 2018-11-15 University Of Massachusetts Bivalent dengue/hepatitis b vaccines
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
MX2022005498A (es) * 2019-11-07 2022-08-11 Inst Microbiology Cas Vacuna del zika/dengue y aplicación de la misma.
CA3198059A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
WO2024081625A1 (en) * 2022-10-11 2024-04-18 University Of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
CA2616026A1 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Also Published As

Publication number Publication date
JP2019520058A (ja) 2019-07-18
CA3025076A1 (en) 2017-11-23
RU2018142835A (ru) 2020-06-22
HUE049543T2 (hu) 2020-09-28
MX2018014198A (es) 2019-08-21
US11028133B2 (en) 2021-06-08
GB2550418A (en) 2017-11-22
GB201719423D0 (en) 2018-01-03
WO2017201543A1 (en) 2017-11-23
KR20190008896A (ko) 2019-01-25
CN109415414A (zh) 2019-03-01
GB201608896D0 (en) 2016-07-06
WO2018215495A1 (en) 2018-11-29
BR112018073681A2 (pt) 2019-02-26
EP3458471A1 (en) 2019-03-27
AU2017268479B2 (en) 2021-04-01
AU2017268479A1 (en) 2018-12-06
US20190300580A1 (en) 2019-10-03
DK3458471T3 (da) 2020-07-06
EP3630796A1 (en) 2020-04-08
IL263054A (en) 2019-01-31
US20200215180A1 (en) 2020-07-09
JP7121396B2 (ja) 2022-08-18
US11401307B2 (en) 2022-08-02
SG11201810157QA (en) 2018-12-28
PH12018502441A1 (en) 2019-05-15
EP3458471B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
PE20190130A1 (es) Secuencias de envoltura de flavivirus variante y usos de las mismas
BR112017027448A2 (pt) vacina contra rsv
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
BR112016013138A2 (pt) mistura de peptídeos
CL2020000466A1 (es) Aditivos para pienso para animales que comprenden un polipéptido que tiene actividad proteasa y usos de estos.
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
BR112018076215A2 (pt) partículas e composições de nicotina
PH12018502465A1 (en) Mic-1 compounds and use thereof
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
EA201792362A1 (ru) Композиции и способы для лечения целиакии спру
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
DK3630977T3 (da) Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
DK3774859T3 (da) Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
MX2016007407A (es) Peptidos resistentes a proteasa.
DK3509573T3 (da) Farmaceutiske sammensætninger til indgivelse af peptid
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
PH12017550134A1 (en) Il-37 variants
CO2021007354A2 (es) Péptido inhibidor de calicreína 5 (klk5)